New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...
The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...
Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...
The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...
RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...
The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...
RSV season is beginning, but for the first time, parents can access an effective treatment to protect their infants from this common but dangerous virus.
University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.
Respiratory syncytial virus (RSV) is an infectious respiratory disease that can look and sound a lot like a cold, with ...
RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...